Имя: Etelcalcetide
Номер КАС. : 1262780-97-1
Последовательность: N-acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-D-argininamide disulfide with L-cysteine hydrochloride
Молекулярная формула: C38H74ClN21O10S2
Молекулярный вес : 1084.71
Чистота: >98.0%
Источник: синтетический
Этелкальцетид представляет собой кальцимиметический и кальций-чувствительный рецептор. (КаСР) agonist composed of a synthetic peptide comprised of seven D-amino acids that can be used to treat secondary hyperparathyroidism (sHPT) in hemodialysis patients with chronic kidney disease (CKD). Upon intravenous administration, etelcalcetide mimics calcium and allosterically binds to and activates the CaSR expressed by the parathyroid gland. Это подавляет синтез и секрецию паратгормона. (ПТХ), тем самым снижая уровни ПТГ и снижая уровни кальция и фосфора в сыворотке крови.. Повышенный уровень ПТГ часто наблюдается у пациентов с ХБП и связан с нарушением регуляции кальций-фосфатного гомеостаза..
Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session.Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.
Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
